Cellectis S.A Net Income 2015-2021 | CLLS

Cellectis S.A net income from 2015 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Cellectis S.A Annual Net Income
(Millions of US $)
2020 $-81
2019 $-102
2018 $-79
2017 $-99
2016 $-67
2015 $-23
2014 $0
Cellectis S.A Quarterly Net Income
(Millions of US $)
2021-09-30 $-37
2021-06-30 $-40
2021-03-31 $-12
2020-12-31 $-39
2020-09-30 $-30
2020-06-30 $-32
2020-03-31 $20
2019-12-31 $-37
2019-09-30 $-16
2019-06-30 $-33
2019-03-31 $-15
2018-12-31 $-23
2018-09-30 $-23
2018-06-30 $-7
2018-03-31 $-25
2017-12-31 $-27
2017-09-30 $-26
2017-06-30 $-27
2017-03-31 $-20
2016-12-31 $-14
2016-09-30 $-14
2016-06-30 $-7
2016-03-31 $-33
2015-12-31 $9
2015-09-30 $-14
2015-06-30 $-25
2015-03-31 $7
2014-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.301B $0.082B
Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81